Skip to main content
Journal cover image

Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.

Publication ,  Journal Article
Boskovitz, A; Akabani, GH; Pegram, CN; Bigner, DD; Zalutsky, MR
Published in: Nucl Med Biol
April 2004

We have obtained encouraging responses in recent Phase I studies evaluating (131)I-labeled human/murine chimeric 81C6 anti-tenascin monoclonal antibody (ch81C6) administered into surgically-created tumor resection cavities in brain tumor patients. However, because the blood clearance is slow, hematologic toxicity has been higher than seen with murine 81C6 (mu81C6). In the current study, a series of paired-label experiments were performed in athymic mice bearing subcutaneous D-245 MG human glioma xenografts to compare the biodistribution of the fragment ch81C6 F(ab')(2) labeled using Iodogen to a) intact ch81C6, b) mu81C6, and c) ch81C6 F(ab')(2) labeled using N-succinimidyl 3-[(131)I]iodobenzoate. Tumor retention of radioiodine activity for the F(ab')(2) fragment was comparable to that for intact ch81C6 for the first 24 h and to that for mu81C6 for the first 48 h; as expected, blood and other normal tissue levels declined faster for ch81C6 F(ab')(2.) Radiation dosimetry calculations suggest that (131)I-labeled ch81C6 F(ab')(2) may warrant further evaluation as a targeted radiotherapeutic for the treatment of brain tumors.

Duke Scholars

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

April 2004

Volume

31

Issue

3

Start / End Page

345 / 355

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tissue Distribution
  • Recombinant Fusion Proteins
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Radiation Dosage
  • Organ Specificity
  • Nuclear Medicine & Medical Imaging
  • Mice, Nude
  • Mice
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boskovitz, A., Akabani, G. H., Pegram, C. N., Bigner, D. D., & Zalutsky, M. R. (2004). Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol, 31(3), 345–355. https://doi.org/10.1016/j.nucmedbio.2003.10.008
Boskovitz, Abraham, Gamal H. Akabani, Charles N. Pegram, Darrell D. Bigner, and Michael R. Zalutsky. “Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.Nucl Med Biol 31, no. 3 (April 2004): 345–55. https://doi.org/10.1016/j.nucmedbio.2003.10.008.
Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol. 2004 Apr;31(3):345–55.
Boskovitz, Abraham, et al. “Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.Nucl Med Biol, vol. 31, no. 3, Apr. 2004, pp. 345–55. Pubmed, doi:10.1016/j.nucmedbio.2003.10.008.
Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl Med Biol. 2004 Apr;31(3):345–355.
Journal cover image

Published In

Nucl Med Biol

DOI

ISSN

0969-8051

Publication Date

April 2004

Volume

31

Issue

3

Start / End Page

345 / 355

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tissue Distribution
  • Recombinant Fusion Proteins
  • Radiopharmaceuticals
  • Radioimmunotherapy
  • Radiation Dosage
  • Organ Specificity
  • Nuclear Medicine & Medical Imaging
  • Mice, Nude
  • Mice